4/16
02:03 pm
pali
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.
Medium
Report
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.
4/16
01:22 pm
pali
Rating for PALI
Low
Report
Rating for PALI